MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%
Last update at 2024-10-30T18:53:00Z
A non-opioid pain med, a COVID-flu shot combo, and more: 7 drug launches to watch in 2025
Fri 25 Oct 24, 09:00 AMOzempic May Reduce the Risk of Alzheimer’s. That’s Huge for Novo Nordisk.
Thu 24 Oct 24, 02:37 PMI'm a pharmacist. Knockoff Ozempic and other weight loss products have serious hidden risks
Mon 21 Oct 24, 01:55 PMMarket Chatter: Eli Lilly Files Suits Against Companies Selling Weight-Loss Drug
Mon 21 Oct 24, 12:12 PM1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now
Sat 19 Oct 24, 10:10 PMFDA not planning to take action against GLP-1 compounders, Endpoints says
Sat 19 Oct 24, 07:20 PMInvesting $10,000 in Each of These 3 Stocks 10 Years Ago Would Have Made You $1.1 Million
Sat 19 Oct 24, 09:00 AMEli Lilly (LLY): Revenue Boost from Zepbound and Mounjaro Amid Strong Market Projections
Fri 18 Oct 24, 07:25 PMJim Cramer Says Novo Nordisk A/S (NVO) ‘Doesn’t Hold A Candle To Eli Lilly’
Fri 18 Oct 24, 01:16 AMLilly Loses Around $14B This Week: How to Play LLY Stock
Thu 17 Oct 24, 07:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 6806.40M | 6155.50M | 7229.90M | 5265.90M | 3680.10M |
| Minority interest | - | - | 183.60M | 92.20M | 1080.40M |
| Net income | 6244.80M | 5581.70M | 6193.70M | 4637.90M | 3232.00M |
| Selling general administrative | 6440.40M | 6431.60M | 6121.20M | 6213.80M | 5975.10M |
| Selling and marketing expenses | - | - | - | 6213.80M | 5975.10M |
| Gross profit | 21911.60M | 21005.60M | 19056.50M | 17598.30M | 16811.60M |
| Reconciled depreciation | 1522.50M | 1547.60M | 1323.90M | 1232.60M | 1609.00M |
| Ebit | 7127.30M | 6357.10M | 6058.00M | 4974.30M | 8036.10M |
| Ebitda | 9433.50M | 8739.10M | 7641.20M | 6604.70M | 9645.10M |
| Depreciation and amortization | 2306.20M | 2382.00M | 1583.20M | 1630.40M | 1609.00M |
| Non operating income net other | -320.90000M | - | - | 291.60M | 74.80M |
| Operating income | 7127.30M | 6357.10M | 6058.00M | 4974.30M | 6186.80M |
| Other operating expenses | 20261.00M | 20770.30M | 17690.20M | 16530.00M | 15708.00M |
| Interest expense | 331.60M | 339.80M | 359.60M | 400.60M | 272.10M |
| Tax provision | 561.60M | 573.80M | 1036.20M | 628.00M | 563.70M |
| Interest income | 268.80M | 314.40M | 326.60M | 80.40M | 161.30M |
| Net interest income | -268.80000M | -314.40000M | -326.60000M | -320.20000M | -110.80000M |
| Extraordinary items | - | 0.00000M | 0.00000M | 3680.50M | -93.90000M |
| Non recurring | 244.60M | - | - | 815.20M | 2465.90M |
| Other items | - | - | - | - | - |
| Income tax expense | 561.60M | 573.80M | 1036.20M | 628.00M | 529.50M |
| Total revenue | 28541.40M | 28318.40M | 24539.80M | 22319.50M | 21493.30M |
| Total operating expenses | 13631.20M | 13457.50M | 12206.90M | 11808.80M | 11026.30M |
| Cost of revenue | 6629.80M | 7312.80M | 5483.30M | 4721.20M | 4681.70M |
| Total other income expense net | -320.90000M | -201.60000M | 1171.90M | 291.60M | -2105.20000M |
| Discontinued operations | - | - | - | 3680.50M | 81.40M |
| Net income from continuing ops | 6244.80M | 5581.70M | 6193.70M | 4637.90M | 3232.00M |
| Net income applicable to common shares | 6244.80M | 5581.70M | 6193.70M | 8318.40M | 3232.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 49489.80M | 48806.00M | 46633.10M | 39286.10M | 43908.40M |
| Intangible assets | 7206.60M | 7691.90M | 7450.00M | 6618.00M | 1068.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2954.10M | 2530.60M | 2871.50M | 2538.90M | 2146.50M |
| Total liab | 38714.40M | 39651.20M | 40807.90M | 36587.00M | 32999.30M |
| Total stockholder equity | 10649.80M | 8979.20M | 5641.60M | 2606.90M | 9828.70M |
| Deferred long term liab | 87.30M | - | - | 2187.50M | - |
| Other current liab | 13706.50M | 3027.50M | 2750.30M | 2189.40M | 9174.80M |
| Common stock | 594.10M | 596.30M | 598.20M | 598.80M | 661.00M |
| Capital stock | 594.10M | 596.30M | 598.20M | 598.80M | 661.00M |
| Retained earnings | 10042.60M | 8958.50M | 7830.20M | 4920.40M | 11395.90M |
| Other liab | 6130.40M | 8674.20M | 11029.00M | 10481.40M | 11870.00M |
| Good will | 4073.00M | 3892.00M | 3766.50M | 3679.40M | 1366.60M |
| Other assets | 7129.90M | 6380.00M | 9274.00M | 4748.30M | 10910.00M |
| Cash | 2067.00M | 3818.50M | 3657.10M | 2337.50M | 7320.70M |
| Cash and equivalents | 2067.00M | 3818.50M | 3657.10M | 2337.50M | 7320.70M |
| Total current liabilities | 17138.20M | 15052.70M | 12481.60M | 11775.20M | 11888.10M |
| Current deferred revenue | - | 8816.30M | 8115.90M | 6681.20M | 404.00M |
| Net debt | 14171.60M | 13066.20M | 12938.20M | 13466.40M | 2977.90M |
| Short term debt | 1501.10M | 1538.30M | 8.70M | 1499.30M | 1102.20M |
| Short long term debt | 1501.10M | 1538.30M | 8.70M | 1499.30M | 1131.20M |
| Short long term debt total | 16238.60M | 16884.70M | 16595.30M | 15803.90M | 10298.60M |
| Other stockholder equity | 3857.70M | 3767.50M | 3709.60M | 3611.30M | 3501.00M |
| Property plant equipment | 10144.00M | 8985.10M | 8681.90M | 7872.90M | 8919.50M |
| Total current assets | 18034.50M | 18452.40M | 17462.10M | 13709.60M | 20549.60M |
| Long term investments | 2901.80M | 3212.60M | 2966.80M | 1962.40M | 2020.70M |
| Net tangible assets | -629.80000M | -4014.80000M | -5574.90000M | -7690.50000M | 1960.20M |
| Short term investments | 144.80M | 90.10M | 24.20M | 101.00M | 88.20M |
| Net receivables | 8558.90M | 8127.20M | 6929.00M | 5541.50M | 5776.80M |
| Long term debt | 14737.50M | 15346.40M | 16586.60M | 13817.90M | 11639.70M |
| Inventory | 4309.70M | 3886.00M | 3980.30M | 3190.70M | 3098.10M |
| Accounts payable | 1930.60M | 1670.60M | 1606.70M | 1405.30M | 1207.10M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 125.60M | - | - | 92.20M | 1080.40M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3844.60000M | -4343.10000M | -6496.40000M | -6523.60000M | -5729.20000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 594.10M | - | 598.20M | 598.80M | 661.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 10042.60M | - | - | 4920.40M | 11395.90M |
| Treasury stock | - | -52.70000M | -55.70000M | -60.80000M | -69.40000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 4337.00M | 4082.70M | 3475.40M | 2339.10M | 8309.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 31455.30M | 30353.60M | 29171.00M | 25576.50M | 23358.80M |
| Capital lease obligations | - | - | - | 486.70M | - |
| Long term debt total | 14737.50M | 15346.40M | 16586.60M | 13817.90M | 11639.70M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -244.00000M | -166.00000M | 516.70M | 456.20M | 5111.90M |
| Change to liabilities | 1678.30M | -664.10000M | 1271.30M | -699.00000M | -409.80000M |
| Total cashflows from investing activities | -3261.60000M | -2762.30000M | -2258.90000M | -8082.90000M | 1906.00M |
| Net borrowings | -62.00000M | 501.40M | 291.60M | 4685.40M | -729.30000M |
| Total cash from financing activities | -5406.70000M | -4131.30000M | -3137.10000M | -2324.50000M | -5904.90000M |
| Change to operating activities | -793.50000M | 1515.40M | -457.10000M | -602.30000M | -980.00000M |
| Net income | 6244.80M | 5581.70M | 6193.70M | 8318.40M | 3232.00M |
| Change in cash | -1751.50000M | 161.40M | 1319.60M | -5660.70000M | 1462.00M |
| Begin period cash flow | 3818.50M | 3657.10M | 2337.50M | 7998.20M | 6536.20M |
| End period cash flow | 2067.00M | 3818.50M | 3657.10M | 2337.50M | 7998.20M |
| Total cash from operating activities | 7084.40M | 7260.70M | 6499.60M | 4836.60M | 5524.50M |
| Issuance of capital stock | - | - | - | - | 1659.70M |
| Depreciation | 1522.50M | 1547.60M | 1323.90M | 1232.60M | 1609.00M |
| Other cashflows from investing activities | -1163.30000M | 24.30M | 102.80M | -7505.20000M | -1995.30000M |
| Dividends paid | -3535.80000M | -3086.80000M | -2687.10000M | -2409.80000M | 2311.80M |
| Change to inventory | -599.70000M | -235.90000M | -533.40000M | -258.70000M | 7.80M |
| Change to account receivables | -299.60000M | -1278.30000M | -1350.00000M | -127.20000M | -10763.50000M |
| Sale purchase of stock | -1500.00000M | -1250.00000M | -500.00000M | -4400.00000M | -4150.70000M |
| Other cashflows from financing activities | 1189.10M | -295.90000M | -241.60000M | -200.10000M | -93.00000M |
| Change to netincome | -668.40000M | 1154.00M | -270.60000M | 653.30M | 3062.20M |
| Capital expenditures | 2484.00M | 1873.20M | 2029.10M | 1353.50M | 3018.20M |
| Change receivables | -299.60000M | - | - | -127.20000M | -996.70000M |
| Cash flows other operating | -793.50000M | - | - | -602.30000M | -980.00000M |
| Exchange rate changes | - | - | - | -89.90000M | -63.60000M |
| Cash and cash equivalents changes | -1583.90000M | - | - | -5660.70000M | 1462.00M |
| Change in working capital | -14.50000M | -1022.60000M | -747.40000M | -1687.20000M | -2378.70000M |
| Stock based compensation | 371.10M | 342.80M | 308.10M | 312.40M | 279.50M |
| Other non cash items | 1145.70M | 1613.50M | -444.20000M | -3402.00000M | 2455.90M |
| Free cash flow | 4600.40M | 5387.50M | 4470.50M | 3483.10M | 2506.30M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company |
-72.079 7.98% | 831.50 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
0.53 0.33% | 160.62 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
11.54 6.09% | 200.99 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
| MRK Merck & Company Inc |
0.77 0.74% | 104.50 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
| AZN AstraZeneca PLC ADR |
-2.075 2.76% | 73.14 | 38.69 | 16.31 | 4.67 | 5.46 | 5.20 | 17.74 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Lilly Corporate Center, Indianapolis, IN, United States, 46285
| Name | Title | Year Born |
|---|---|---|
| Mr. David A. Ricks | Chairman, CEO & Pres | 1968 |
| Ms. Anat Ashkenazi | Sr. VP & CFO | 1972 |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs | 1974 |
| Mr. Diogo Rau | Sr. VP & Chief Information and Digital Officer | NA |
| Mr. Jacob S. Van Naarden | Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology | 1985 |
| Mr. Donald A. Zakrowski | Chief Accounting Officer & VP of Fin. | NA |
| Mr. Martin Bott MIBS | VP of Fin. & Special Projects | 1963 |
| Ms. Anat Hakim J.D. | Sr. VP, Gen. Counsel & Sec. | 1969 |
| Mr. Alonzo Weems | Sr. VP and Chief Ethics & Compliance Officer | NA |
| Ms. Leigh Ann Pusey | Sr. VP of Corp. Affairs & Communications | 1963 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...